Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Camille Vong

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
The AAPS Journal|February 22, 2012
Rapid sample size calculations for a defined likelihood ratio test-based power in mixed-effects modelsCamille Vong, Martin Bergstrand, Joakim Nyberg, et al.
American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions|March 26, 2021
Modeling of Survival and Frequency of Cardiovascular-Related Hospitalization in Patients with Transthyretin Amyloid Cardiomyopathy Treated with TafamidisCamille Vong, Martin Boucher, Steve Riley, et al.
Journal of Neurology|August 30, 2024
Sparse item testing of clinical scales in neurology trials to alleviate burden to patientsChao Chen, Ana Novakovic, Kris Jamsen, et al.
CPT: Pharmacometrics & Systems Pharmacology|March 2, 2026
Causal Directed Acyclic Graphs to Mitigate Confounding Bias in Exposure-Response AnalysesSebastiaan C Goulooze, Camille Vong, Chuanpu Hu, et al.
CPT: Pharmacometrics & Systems Pharmacology|February 1, 2024
Tofacitinib pharmacokinetics in children and adolescents with juvenile idiopathic arthritisCheng Chang, Camille Vong, Xiaoxing Wang, et al.
Clinical Pharmacology in Drug Development|January 29, 2021
Population Pharmacokinetics of Tofacitinib in Patients With Moderate to Severe Ulcerative ColitisCamille Vong, Steven W Martin, Chenhui Deng, et al.
CPT: Pharmacometrics & Systems Pharmacology|December 8, 2021
Development of a model-based clinical trial simulation platform to optimize the design of clinical trials for Duchenne muscular dystrophyKarthik Lingineni, Varun Aggarwal, Juan Francisco Morales, et al.
Journal of Pharmacokinetics and Pharmacodynamics|May 26, 2019
Towards regulatory endorsement of drug development tools to promote the application of model-informed drug development in Duchenne muscular dystrophyDaniela J Conrado, Jane Larkindale, Alexander Berg, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
The AAPS Journal|February 22, 2012
Rapid sample size calculations for a defined likelihood ratio test-based power in mixed-effects modelsCamille Vong, Martin Bergstrand, Joakim Nyberg, et al.
American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions|March 26, 2021
Modeling of Survival and Frequency of Cardiovascular-Related Hospitalization in Patients with Transthyretin Amyloid Cardiomyopathy Treated with TafamidisCamille Vong, Martin Boucher, Steve Riley, et al.
Journal of Neurology|August 30, 2024
Sparse item testing of clinical scales in neurology trials to alleviate burden to patientsChao Chen, Ana Novakovic, Kris Jamsen, et al.
CPT: Pharmacometrics & Systems Pharmacology|March 2, 2026
Causal Directed Acyclic Graphs to Mitigate Confounding Bias in Exposure-Response AnalysesSebastiaan C Goulooze, Camille Vong, Chuanpu Hu, et al.
CPT: Pharmacometrics & Systems Pharmacology|February 1, 2024
Tofacitinib pharmacokinetics in children and adolescents with juvenile idiopathic arthritisCheng Chang, Camille Vong, Xiaoxing Wang, et al.
Clinical Pharmacology in Drug Development|January 29, 2021
Population Pharmacokinetics of Tofacitinib in Patients With Moderate to Severe Ulcerative ColitisCamille Vong, Steven W Martin, Chenhui Deng, et al.
CPT: Pharmacometrics & Systems Pharmacology|December 8, 2021
Development of a model-based clinical trial simulation platform to optimize the design of clinical trials for Duchenne muscular dystrophyKarthik Lingineni, Varun Aggarwal, Juan Francisco Morales, et al.
Journal of Pharmacokinetics and Pharmacodynamics|May 26, 2019
Towards regulatory endorsement of drug development tools to promote the application of model-informed drug development in Duchenne muscular dystrophyDaniela J Conrado, Jane Larkindale, Alexander Berg, et al.
Pageof 1